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Abstract
The purpose of this study was to find out the beneficial effects of curcumin and 
vitamin D3 in rats treated with scopolamine as to generate animal model of tauopa-
thies, i.e., neurodegenerative disorders, including Alzheimer’s disease (AD). Abnormal 
phosphorylation of tau results in the transformation of normal adult tau into paired-
helical-filament (PHF) tau and neurofibrillary tangles (NFTs). Our results indicated 
that scopolamine-treated rats exhibit increased levels of hyperphosphorylated tau 
protein along with PHF, and curcumin and vitamin D3 lowered the levels of PHF 
better than donepezil. The effect of abnormal hyperphosphorylation of tau was also 
detected in the hematoxylin and eosin staining of brain tissues as well as in the western 
blot analyses in our experimental rat models of AD. This abnormal level of hyperphos-
phorylated tau probably causes cognitive and memory deficit as observed in different 
behavioral tests on exploratory groups. Hyperphosphorylated tau may have disrupted 
the microtubule network in experimental rats. Signs of temporal region dementia 
noted during behavioral studies may be linked to the neurodegeneration and abnormal 
hyperphosphorylation of tau observed in our experimental animal model of AD. The 
curcumin and vitamin D3-treated group presented lower levels of hyperphosphory-
lated tau and a better behavioral response. Thus, inhibition of abnormal hyperphos-
phorylation of tau offers a promising therapeutic target for AD and related tauopathies.
Keywords: Alzheimer’s disease, memory impairment, inflammation, scopolamine, 
curcumin, vitamin D3, donepezil
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder, which present mainly 
in the elderly patients. It is characterized by progressive loss of cognitive functions, 
amyloid β (Aβ) deposition, and formation of paired-helical-filament (PHF) tau and 
neurofibrillary tangles (NFTs) in the brain cells. NFTs are formed inside the cell 
bodies of the neurons. These NFTs cause shrinkage of neurons and resultant loss of 
cognition and learning [1, 2].
Mental Disorders
2
Tau protein is a highly soluble microtubule-associated protein found abundantly 
in the neuronal cells of the central nervous system (CNS). Tau proteins are the prod-
uct of alternative splicing from a single gene, designated for microtubule-associated 
protein tau (MAPT) in humans, located on chromosome 17. There are six isoforms of 
tau found in the human brain. They can be distinguished by their binding domains. 
Tau has 79 potential phosphorylation sites on the longest isoform [3]. Tau is the major 
microtubule-associated protein of a mature neuron. The other two neuronal MAPs 
are MAP1 and MAP2, which are involved in tubulin interaction and promotion of its 
assembly into microtubules and stabilization of the microtubule network [4].
Normal adult human brain contains 2–3 moles of phosphorylated tau protein. 
Hyperphosphorylation of tau decreases its normal function. In Alzheimer’s dis-
ease, brain tau is approximately three- to fourfold more hyperphosphorylated 
than the normal adult brain. This hyperphosphorylated state polymerized into 
paired-helical-filament tau and when mixed with straight filaments (SF) formed 
neurofibrillary tangles (NFT). The hyperphosphorylated tau in AD brain has the 
ability to sequester normal tau, MAP1, and MAP2, to disrupt microtubules, and to 
self-assemble into PHF/SF. Abnormal hyperphosphorylated tau, in the cytosol, does 
not polymerized into PHF [5]. The cytosolic hyperphosphorylated tau is involved 
in tubulin assembly but inhibiting its normal assembly and disrupting microtubule 
[6]. In addition, with hyperphosphorylation of tau, conformational changes and 
abnormal cleavage of tau may contribute to the pathogenesis of AD [7, 8]. Tau 
hyperphosphorylation has been reported in AD and other tauopathies; thus, the 
inhibition of abnormal hyperphosphorylation of tau offers a promising therapeutic 
target for AD and related tauopathies [9].
Similarly, oxidative stress is also strongly linked to neuronal dysfunction and 
neuronal cell death [10]. It is suggested that oxidative stress plays a significant role 
in the pathological conditions of AD by enhancing Aβ deposition, tau phosphoryla-
tion, and loss of synapses and neurons [11].
Reactive oxygen species (ROS) are by-products of biochemical and physiologi-
cal processes in the body and can cause oxidative damage to macromolecules in an 
uncontrolled manner that may lead to many chronic diseases. Thus, overproduction 
of ROS is a hallmark of neurodegenerative disorders and other diseases [12, 13].
Neuroinflammation also causes neurodegeneration in the vulnerable regions of 
the brain such as the hippocampus. Microglia and astrocytes play important roles in 
neuroinflammation and contribute to neurological disorders [14, 15].
Previous studies showed that curcumin acts as an antioxidant by activating 
macrophages to remove ROS-like, superoxide anions, H2O2, and nitrite radicals. 
Its anti-inflammatory properties were tested in vivo and in vitro on animals 
in acute and chronic inflammatory conditions [16]. Moreover, vitamin D also 
reported to play a part in the cerebral processes of detoxification by interact-
ing with reactive oxygen and nitrogen species in the rat brain and by regulating 
the activity of glutamyl transpeptidase [17, 18], which is a key enzyme in the 
metabolism of glutathione. Vitamin D3 is the active form of vitamin D. This study 
investigated the effects of curcumin and vitamin D3 on memory and learning, by 
assessing the behavioral responses of scopolamine-induced learning-impaired 
rats through assays involving the locomotive and maze activities and histological 
and protein analysis in the rat brain tissues. The findings of this study show that 
inducing learning impairment in rats by using scopolamine followed by treat-
ment with curcumin and vitamin D3 results in neuroprotection and attenuation 
of cognitive deficits as shown by reduced brain tissue damage in histoanalysis, 
decreased accumulation of abnormal proteins with immunoblot analysis and 
increased in the numbers of correct responses to behavioral stimuli during 
locomotive and maze tests.
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2. Literature review
Aging is the primary risk factor for AD development. Aged population is prone 
to oxidative stress that results in the degeneration of their brains [19, 20]. Diets 
containing saturated fat and less intake of vitamin E and C are linked with the 
risk of AD [20]. AD patients suffer from memory impairment along with other 
cognitive deficits such as language, visuospatial skills, insight, and apraxia. Most 
patients may suffer from other symptoms such as depression, hallucination, 
apathy, and delusions at later stages of AD [21]. Numerous studies have indicated 
that accumulation of amyloid beta proteins (Aβ) and phosphorylated tau (p-tau) 
are the key pathological hallmarks of AD [22]. Similarly, oxidative stress changes 
ionic homeostasis and other biochemical parameters, which ultimately causes 
neuronal dysfunction and cell death leading to progressive dementia associated 
with extensive Aβ and tau pathology [23]. Tau is a neuronal microtubule-associ-
ated protein that is responsible for maintaining the microtubule dynamics and its 
function of transportation by axons and neurite outgrowth [24]. Animal models 
have demonstrated that loss of synaptic plasticity is one of the key components in 
the neurodegenerative process of AD, and tau is one of the contributing factors 
for neurodegeneration [25]. Literature indicated that the oxidative stress plays 
a significant role in the pathology of AD by enhancing Aβ deposition, tau phos-
phorylation, and loss of synapses and neurons [26].
Vitamin D is a group of fat-soluble secosteroids that helps to absorb calcium, 
magnesium, phosphate, iron, and zinc. Vitamin D protects the brain from the 
degenerative processes of AD by binding itself with vitamin D receptors [27]. 
Vitamin D deficiency has been associated with neurological and psychiatric disor-
ders. Previous studies revealed that it controls Ca2+ homeostasis in the hippocampus 
by regulating intracellular Ca2+. It also controls neurotrophic agents and protects 
the brain from Aβ-42 accumulation by stimulating phagocytosis. It also protects 
acetylcholine deficiency by increasing the activity of choline acetyltransferase in 
the brain. Due to its multiple biological targets, vitamin D can be used as an aide 
with the standard anti-dementia treatment. Among vitamin Ds, the most important 
compound is vitamin D3, also known as cholecalciferol. Increasing evidence high-
lights the impact of vitamin D deficiency as an important factor in various central 
or peripheral neurological diseases, especially multiple sclerosis and other neurode-
generative diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, and 
Alzheimer’s disease [28].
Curcumin (Curcuma longa (Haldi)) was used as a treatment in the animal models 
of AD. It was observed that curcumin reduced the formation of NFTs, Aβ deposi-
tion, and Aβ oligomerization. Curcumin can cross the blood–brain barrier because 
of its lipophilic nature. It can also inhibit acetylcholinesterase (AChE) activities [29] 
and can bind with the plaques leading to the alleviation of behavioral impairment 
[30–31]. Curcumin also acts as an antioxidant by activating macrophages to remove 
ROS-like radicals, superoxide anions, H2O2, and nitrite radicals [32–35].
Donepezil is available with the trade name “Aricept” developed by Eisai Inc. in 
1983. It is a reversible AChE inhibitor, used for the treatment of mild to moderate 
dementia in AD patients. It has a long plasma half-life of 70 h. It is a noncompetitive 
reversible inhibitor of AChE that improves the function of cholinergic transmis-
sion. It increases the concentration of acetylcholine by preventing its hydrolysis. 
Animal studies have shown its selectivity for brain tissues and inhibition of AChE 
activities in smooth, striated, cardiac muscles. It can also inhibit AChE in red blood 
cells similar to its effect at synapses in CNS. AChE inhibition in red blood cells has 
been used as an indicator of the clinical effectiveness of donepezil in Alzheimer’s 
disease patients [36].
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Scopolamine is a tropane alkaloid that acts as a muscarinic receptor antagonist. 
Scopolamine is used to study memory and cognition in animal model of AD. 
Studies have shown that scopolamine provides a suitable pharmacological model 
of memory defect. Scopolamine administration characterizes cognitive deficits 
resulting in the impairment of verbal learning, spatial learning, and reaction time 
[37]. Scopolamine can also have an influence on other neurotransmitter systems due 
to the functional interaction of cholinergic neurons with other neurotransmitter 
systems [38]. Cholinergic transmission is blocked, resulting in cognitive impair-
ment in a rat model of AD [39]. Histological studies of the brain of Alzheimer’s 
patients have revealed the presence of activated microglia and reactive astrocytes 
around the Aβ plaques. The chronic activation of microglia secretes cytokines and 
some reactive substances that exacerbate Aβ pathology; thus, neuroglia plays an 
important part in the pathogenesis of AD [40]. Curcumin has a lipophilic property 
that is capable of passing through all cell membranes and thus exerts its intracel-
lular effects. Curcumin has antiproliferative actions on microglia. A minimal dose 
of curcumin affects the neuroglial proliferation and differentiation. The overall 
effect of curcumin on neuroglial cells involves decreased astrocytes proliferation, 
improved myelogenesis, and increased activity and differentiation of oligodendro-
cytes [40].
3. Aims and objectives of this study
This study was conducted with the following objectives:
1. To determine the effects of curcumin, vitamin D3, and donepezil on behavioral 
responses of scopolamine-induced memory and learning-impaired rats.
2. To examine the structure of brain tissues obtained from scopolamine-treated 
rats with and without curcumin or vitamin D3 or donepezil.
3. To investigate the concentration of hyperphosphorylated tau protein in scopol-
amine-treated rat brain tissues with donepezil, curcumin, or vitamin D3.
4. Material and methods
4.1 Animals
Male Sprague Dawley rats of 200 ± 25 g were obtained from the animal 
house (PAPRSB Institute of Health Sciences Animal Facility, University Brunei 
Darussalam). Thirty animals were divided into five groups of six animals per group 
and reared under a standard laboratory condition with free access to food and 
water. Rats were acclimatized in a laboratory condition for a minimum of 1 week 
before undergoing behavioral test. The food was restricted under a daily feeding 
regime to maintain the weight of the rats.
All experiments were performed during daylight for 27 days, and all groups 
except group I (saline control) received daily scopolamine injection (2.5 mg/kg) to 
induce excitotoxicity. Curcumin, vitamin D3, and donepezil were administered to 
rats orally (Table 1). All experiments were conducted in accordance with institu-
tional ethics guidelines for animal care and use (Table 2).
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4.2 Experimental design
4.2.1 Behavioral tests
4.2.1.1 Rectangular maze
This test was used to investigate learning and memory. The maze consisted of a 
rectangular box with an entry and a reward chamber with food, which were placed 
at the opposite ends of the box (Figure 1). All groups were given training in rectan-
gular maze 1 week before drug administration. Each animal was placed in the same 
spot, recording the time taken by the animal to reach the reward chamber (transfer 
latency). Five readings were taken for each animal, and the average was calculated 
as their learning score [41–43].
Group Treatment
Group 1 Saline control (0.9% saline)
Group 2 Scopolamine (2.5 mg/kg) injection
Group 3 Scopolamine (2.5 mg/kg) injection and curcumin (80 mg/kg) oral
Group 4 Scopolamine (2.5 mg/kg) injection and donepezil (2.5 mg/kg) oral
Group 5 Scopolamine (2.5 mg/kg) injection and vitamin D3 (0.0179 mg/kg) 
oral
Table 1. 
List of treatments received by each of the five groups of rats.
Control Scopolamine Curcumin Vitamin D3 Donepezil
Mean 17.42607 176.1054 27.29171 33.8713571 34.12914
SEM 1.261983 71.34413 14.49811 11.5630538 12.12356
Table 2. 
Data expressed as mean ± standard error of the mean (SEM), expressed as the mean of time taken by different 
groups to reach the reward chamber each alternate day for 27 days.
Figure 1. 
Rectangular maze test.
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Figure 2. 
Actophotometer for locomotor activity.
4.2.1.2 Locomotor activity
Actophotometer was used to measure the locomotor activity (Figure 2). Each 
animal was treated with their respective compound, was placed in actophotometer, 
and was given 2 min in activity cage. When the beam of light falling on photocell 
was cut off due to the movement of the animal, an activity count was recorded. The 
increase or decrease in locomotor activity was then calculated [42, 43].
4.2.2 Histology
After the behavioral study was conducted, the animals were anesthetized, and 
their brains were removed and stored in 4% paraformaldehyde (Figure 3). The 
brains were embedded in paraffin and kept in the refrigerator. Paraffin sections 
(5 μm) were prepared using rotary microtome (Figure 4) and stained with hema-
toxylin and eosin [44]. Photographs were taken for each section.
4.2.3 Estimation of protein concentration
4.2.3.1 Immunoblotting
Curcumin, donepezil, and vitamin D3 reduce tau phosphorylation in the brains 
of a scopolamine-treated rat model of Alzheimer’s disease.
The brain tissues were dissected from the coronal area with clean tools and put 
on ice as quickly as possible to prevent protein degradation by proteases. The tissues 
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were placed in microcentrifuge tubes and immersed in liquid nitrogen to snap-
freeze. They were homogenized on ice after adding 1× ice-cold lysis buffer, rinsed 
twice with the same buffer, and agitated on a shaker for 2 h at 4°C. After centrifuga-
tion for 20 min at 12,000 rpm at 4°C, the supernatant was transferred into a fresh 
tube kept on ice discarding the pellet. A small volume of lysate was sampled to 
perform a protein quantification assay.
After boiling each cell lysate in Tris-buffered saline, 0.1% Tween 20 (TBST) at 
100°C for 5 min, 50 μg of protein was loaded into the wells of the sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel for immunoblot analy-
sis. After gel running for 1–2 h at 100 V, the proteins were then transferred onto 
the membrane and blocked for 1 h at room temperature. The membrane was then 
incubated with 1:1000 dilution of primary antibody in blocking buffer followed by 
washing three times with TBST for 5 min each wash. The membrane was incubated 
with the 1:1000 dilution of conjugated secondary antibody in blocking buffer at 
room temperature for 1 h and washed three times with TBST at 5 min each wash. 
Excess reagents were removed, and the membrane was covered with transparent 
plastic wrap. The image was acquired using the darkroom development techniques 
for chemiluminescence detection.
4.3 Statistical analysis
Data were expressed as mean ± standard error of the mean (SEM). The analysis 
of variance (ANOVA, single factor) was used to measure transfer latency with 
statistical significance set at p < 0.05.
Figure 3. 
Freshly dissected rat brains.
Figure 4. 
Paraffin embedding for immunohistochemistry.
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Figure 5. 
Effect of curcumin, vitamin D3, and donepezil on latency time compared with the disease control group (mean, 
n = 6). The histogram shows the mean of latency time in seconds.
5. Results
5.1 Rectangular maze test
The effects of curcumin and vitamin D3 on scopolamine-induced rats were 
investigated using the rectangular maze test comparing the results obtained with 
that of donepezil, a widely accepted AD standard drug. Rats that were injected 
with scopolamine showed significantly higher transfer latency, indicating the 
longer time for rats to reach the food (nearly 200 s). Also, there was no sign of 
improvement during the successive days (Figure 5). Rats treated with curcumin 
and vitamin D3 displayed significant reduction in transfer latency, which means 
that treated rats did not take a longer time to reach the food, less than 50 s as 
shown in Figure 6. Furthermore, there was a slight reduction in the latency time 
from day to day. The effect of these two compounds was also comparable to that 
of donepezil.
5.2 Locomotor activity
Actophotometer was used to measure locomotor activity by counting total 
photocell counts per rat for 2 min. Rat injected with scopolamine showed progres-
sive decline in their locomotor activity (Figure 7), and average values were shown 
in Table 3 and Figure 8. Rats treated with curcumin and vitamin D3 showed an 
initial increase in locomotor activities then slightly declined after 7 days followed 
by leveling off in the succeeding days. In contrast, rats treated with curcumin and 
vitamin D3 showed high locomotor activity compared with the non-treated control 
rats treated with donepezil that exhibited similar response as those treated with 
curcumin and vitamin D3, suggesting that these two compounds had triggered 
alertness and excitatory activities in scopolamine-treated rats.
5.3 Histology
Non-treated rats injected with scopolamine revealed prominent degeneration 
of cells and decrease number of nuclei in their brain tissues as compared to those 
treated with curcumin and vitamin D3. Moreover, treatment with curcumin, vita-
min D3, and donepezil showed similar cell morphology similar to the control group 
demonstrating brain cells that appeared normal (Figure 9).
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Figure 6. 
Time taken to reach the reward chamber in the rectangular maze. Y-axis represents time in second. Data 
expressed as mean ± SEM.
Figure 7. 
Effect of curcumin, vitamin D3, and donepezil on latency time compared to scopolamine-treated group (mean, 
n = 6). Graph shows mean latency time in seconds.
Control Scopolamine Curcumin Vitamin D3 Donepezil
Mean 12.88686 6.161643 9.911429 11.77929 12.0664286
SEM 3.712271 6.766518 2.502838 3.992999 3.23978538
Table 3. 
Data expressed as mean ± SEM for the total number of photocell counts for each group.
Figure 8. 
Locomotor activities of all rats except scopolamine-treated rats in actophotometer showed no significant difference. 
Data expressed as mean of photocell count (mean ± SEM, n = 6) of animals on each alternate day for 27 days.
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Figure 9. 
Hematoxylin and eosin staining of rat brain tissues: A, control; B, scopolamine-induced; C, curcumin-treated; 
D, vitamin D3-treated; and E, donepezil. The images show no significant difference in the cellular histology 
of the hippocampal area (cornu ammonis) (CA3) in the experimental groups (curcumin, vitamin D3, and 
donepezil) as compared with those of scopolamine group, which showed less number of nuclei stained as 
revealed by H and E staining. Arrows in scopolamine slide B indicated the gaps around the neuronal cells of 
coronal sections (5 μm) at magnification 40×.
5.3.1 Immunoblotting
See Figure 10.
5.3.2 Vitamin D3 + scopolamine
See Tables 4, 5 and Figure 11.
Figure 10. 
Western blot analyses of scopolamine-treated and other treatments (curcumin and vitamin D3 and donepezil) 
groups showing difference in the levels of hyperphosphorylated tau in a rat model of AD. (a) Immunoblot of 
hippocampus homogenates from treated rats (scopolamine, vehicle, treated with curcumin and vitamin D3) 
using the PHF monoclonal antibodies and (b) normalized with β actin.
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6. Discussion
This study investigated the effects of curcumin and vitamin D3 on learning and 
memory and locomotion. The first part of the study involved subjecting the rats to 
several behavioral tests and examining their memory competencies and locomo-
tor responses. Histological studies were also done on rats’ brains to observe the 
changes that have occurred in the brain tissues after various treatments. The results 
obtained from rats treated with curcumin and vitamin D3 were compared with 
S/No. Area Percent
1 13690.4 17.975
2 22076.4 28.986
3 16481.8 21.641
4 10,292 13.513
5 13,621 17.884
Table 4. 
Densitometry data were obtained using image J software, exhibiting relative density of protein from all groups.
S/No. Area Percent
1 4240.34 23.631
2 3502.99 19.522
3 1857.51 10.352
4 4913.31 27.381
5 3429.87 19.114
Table 5. 
Densitometry data were obtained using image J software. Representing relative density of Tau protein for all 
groups.
Figure 11. 
Densitometry data obtained from image J software, presented as relative density of tau protein present in all 
groups.
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donepezil-treated rats. Scopolamine (muscarinic cholinergic antagonist) was used 
to induce memory impairment in rats [45]. Curcumin was selected as the previous 
research showed that curcumin could be used to recover learning and memory 
abilities in rats in AD and other inflammatory conditions [46]. Literature also 
reported that curcumin facilitates learning and memory functions by diminishing 
or preventing lipid peroxidation in the brains of aged rats [47]. In general, curcumin 
is a well-known oxygen free radical scavenger [46].
Vitamin D plays an important role in the regulation of numerous neurotransmit-
ters including acetylcholine, dopamine, serotonin, and gamma aminobutyric acid. 
Several studies have also been reported that vitamin D deficiency is associated 
with neurological dysfunction and that supplementation of vitamin D may induce 
a protective effect against neurological disorders [48]. Based on the results of this 
study, the rats that were injected with scopolamine only revealed a gradual increase 
in the latency time until day 9, indicating a longer time required for rats to reach the 
end of the maze where food as a source of attractive stimuli was placed. After the 
ninth day, the latency time remained high and was three times higher than that of 
curcumin, vitamin D3, and donepezil. Rats treated with curcumin and vitamin D3 
exhibits reduced latency time. A slight increase in time was observed between days 
1 and 7 and gradually decreased up to day 27. The daily decrease in the latency time 
represented the effects of these two compounds on long-term memory. When com-
paring between curcumin and vitamin D3, rats treated with curcumin had slightly 
lower latency time than vitamin D3, suggesting that curcumin was comparatively 
more effective than vitamin D3 and donepezil in improving learning and memory 
among rats. Rats treated with donepezil initially showed low latency time, but 
remained constant until the 27 days. The similarity of latency time values obtained 
among curcumin, vitamin D3, donepezil, and the control suggested that curcumin 
and vitamin D3 have comparable effects like that of donepezil and may reverse the 
memory impairment induced by scopolamine.
The locomotor activity of rats was investigated by placing each rat in an actopho-
tometer for 2 min and then assessing their movement as compared with those treated 
with curcumin and vitamin D3. Furthermore, the results indicated a decline in daily 
activities suggesting signs of slowing down. Vitamin D3 showed an increase in loco-
motor activity, which was comparable with those of donepezil and the controls 
confirming previous studies on the role of vitamin D in motor activities [49].
Curcumin exhibited slightly less action when compared to vitamin D3, done-
pezil treated, and control rats but was still exhibiting higher movements than 
scopolamine only. After 9 days, the locomotor activity for each treatment except 
scopolamine became relatively stable throughout 27 days and did not show any 
signs of slowing down, indicating that rats treated with vitamin D3 and curcumin 
exhibited signs of alertness that continued for a longer time.
The effects of each treatment were also histologically examined in rat brains. 
Sections of the brain tissue from the region of hippocampus were stained to 
investigate histological appearance before and after the treatment with selected 
compound. The cells in the brain tissue treated only with scopolamine exhibited 
less number of nuclei that appeared to be shrunken and smaller than with those 
of the control group. Treatment with curcumin and vitamin D3 showed no 
difference as compared with those of the brain tissue treated with donepezil and 
control group, suggesting that the brain tissues seemed to have recovered after 
the rats were treated with curcumin and vitamin D3. The difference in the levels 
of tau protein was also assessed using immunoblotting. In scopolamine-induced 
group, phosphorylated tau proteins were relatively higher than other groups 
indicating a state of proliferation in the brain tissues. Previous studies reported that 
accumulation of phosphorylated tau protein is one of the hallmarks of AD [50]. 
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Western blot images were also assessed visually by making comparisons between 
bands in different lanes (Figure 10). Densitometry data obtained from image J 
software presented as relative density of tau protein found in all groups (Tables 4 
and 5). After the rats were treated with curcumin and vitamin D3, the levels of tau 
proteins were reduced suggesting an attenuation of phosphorylated tau proteins in 
the rat brains, confirming the earlier studies (Figures 10 and 11) [51, 52].
7. Conclusion
We concluded that Alzheimer’s disease is a progressive neurodegenerative 
disorder characterized by gradual memory loss and shrinkage of neuronal cells par-
ticularly in the hippocampus and basal forebrain regions. Curcumin and vitamin D3 
have biomedical qualities that protect the brain from degeneration associated with 
AD. In this study, the behavioral tasks involving rectangular maze test and locomo-
tor activity were used to determine if curcumin and vitamin D3 could improve 
learning and memory among rats subjected to scopolamine-induced impaired 
cognition. With cognitive impairment, the correct response rate of animals during 
acquisition and retention period was significantly lower than that of the control 
group. However, treatment with curcumin and vitamin D3 has increased their cor-
rect response rate for both tasks that became equal with those of the control group 
(p < 0.05). Tissue analysis by H and E staining of the rat brain from the scopol-
amine group showed less number of cells, which was improved upon the treatment 
with curcumin and vitamin D3, resulting in significantly increase in the number of 
cells with no gap around them. This was accompanied by reduced level of abnormal 
tau proteins detected via immunoblot analysis. Together, these findings demon-
strate that curcumin and vitamin D3 have the potential to reverse some cognitive 
deficits, correct memory impairment, and protect the brain from degeneration.
The animal model of AD has shown improvement in learning and memory after 
exposure to curcumin and vitamin D3 treatment, which slowed down the progress 
of AD pathologies delaying the onset of AD. With potential as a treatment for AD in 
future, the active structure and the target of both curcumin and vitamin D3 can be 
further investigated to elucidate the molecular mechanism by which their beneficial 
effects can be enhanced for the improvement of AD patients. Vitamin D due to its 
multiple biological targets can be used as an adjunct to standard anti-dementia 
treatment in AD. Curcumin has intensively been studied for the improvement of 
AD symptoms, and existing investigations on inhalable curcumin and ar-turmerone 
on neural stem cells (NSCs) are currently under clinical trials.
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